The Golgi apparatus, M-COPA (2-methylcoprophilinamide), might be a promising therapeutic target to conquer the detrimental cycle of TKI resistance in EGFR-mutated NSCLC cells via downregulating cell surface RTK expression [122]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.